Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 15/20 | 0.71 |
| ▸ | RARG | P13631 | 15/20 | 0.71 |
| ▸ | RARA | P10276 | 14/20 | 0.71 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.71 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | BLVRB | P30043 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 5/20 | 0.57 |
| ▸ | RXRB | P28702 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723495 | 0.89 | RARB (0.74) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2391376 | 0.83 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL9747007 | 0.83 | RARA (0.62) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL2331952 | 0.82 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL846110 | 0.81 | RARB (0.81) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL29827631 | 0.81 | RARB (0.81) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL9747842 | 0.81 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL5680238 | 0.81 | RXRA (0.81) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL5680234 | 0.80 | RARB (0.69) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL26306683 | 0.80 | CYP3A4 (0.53) | RARBRARGRARACYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223913-B1 | USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARS-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION | GALDERMA RES & DEV (FR) | 2006-03-08 | — | — | EP | claimed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | claimed |
| US-20020049249-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2002-04-25 | — | — | US | claimed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | claimed |
| US-20050112123-A1 | Methods of treating proteinuria | WASHINGTON, UNIVERSITY OF | 2005-05-26 | — | — | US | disclosed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | disclosed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-6506796-B1 | Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020049249-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2002-04-25 | — | — | US | disclosed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
| US-20020049249-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | RARB 14/4885RARG 11/4885RARA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.